2015
Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma
Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 2015, 125: 1883-1889. PMID: 25605368, PMCID: PMC4375715, DOI: 10.1182/blood-2014-09-600924.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaEfficacy of mogamulizumabT-cell lymphomaAnti-CC chemokine receptor 4 monoclonal antibodyFrequent treatment-emergent adverse eventsCutaneous T-cell lymphoma patientsTreatment-emergent adverse eventsT-cell lymphoma patientsSignificant hematologic effectsInfusion-related reactionsPhase 1/2 studyOverall response ratePhase 3 investigationAnti-CCR4 antibodyEvaluable patientsBlood involvementAdverse eventsGrade 1/2Sézary syndromeComplete responseMycosis fungoidesLymphoma patientsHematologic effectsDisease progressionMogamulizumab
1989
Effects of Intravenous Fat Infusion on Neonatal Neutrophil and Platelet Function
Herson V, Block C, Eisenfeld L, Maderazo E, Krause P. Effects of Intravenous Fat Infusion on Neonatal Neutrophil and Platelet Function. Journal Of Parenteral And Enteral Nutrition 1989, 13: 620-622. PMID: 2515309, DOI: 10.1177/0148607189013006620.Peer-Reviewed Original ResearchConceptsPolymorphonuclear leukocytesIntralipid infusionNeonatal intensive care unitAdult polymorphonuclear leukocytesIntensive care unitIntravenous fat infusionPresence of infectionAdverse hematologic effectsNeonatal polymorphonuclear leukocytesParenteral nutritionIll neonatesNeonatal neutrophilsPMN countCare unitPlatelet countPlatelet activityHematologic effectsIntravenous fatPlatelet functionPlatelet numberUnchanged preFat infusionPlatelet aggregationInfusionIntralipid
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply